

Peak Asset Management's latest Corporate Opportunity, Lifespot Health, is now live. Bids close Wednesday 10am given exceptional demand. Peak's last three deals (DTZ, CFO, NTI) are up over 100% since listing as at close on Friday, 2 December 2016.



Lifespot Health is focussed on the management and monitoring of chronic diseases (Telehealth is in a hot space right now) and one of (if not the only) globally certified platform that is device agnostic, a huge “unique selling proposition” to the other hardware companies...just think RAP, CMP, MDR, RMD, COH... potentially being able to integrate their devices and grow market share?

The Company already has large paying clients, which include AnyCare and B.BRAUN (a \$9BN AUD revenue per year “juggernaut”, that is about to “pull the trigger” on a new diabetics device that will integrate with Lifespot’s back end), a huge tick.


The management is highly qualified that with a proven track record of delivering shareholder value. Stefan Shraps, Chief Executive Officer of Lifespot Health, was previously the COO for a software & encryption business that he listed on the German Exchange (150x over-subscribed and on day 1, reaching over \$1BN EUR market cap) – he certainly knows how to create shareholder value.

“Our technology is already operational in Europe, with existing paying customers including B.Braun, Anycare and TK Pharma“, Stefan said.

[CLICK HERE](#) to bid for stock

He describes the BodyTel technology as an “end-to-end” solution for managing chronic diseases. Patients do not need to visit the hospital as analysis can be done in real-time with BodyTel devices. Lifespot Skin is a secondary focus, with technology which has the potential to revolutionise management, monitoring and analyses of skin diseases in a similar way.

How BodyTel(TM) Works



Big Data is the play here with a SaaS revenue stream allowing the device companies to create “smart-medically approved devices”. The market is valued >\$35BN according to Goldman Sachs by 2020...

The business is already cash-flow break even (based on the past few months) and this is without B.BRAUN’s SaaS based revenues kicking in 2Q 2017...

Lifespot has large opportunities to scale the business internationally without large CAPEX and potential SaaS based revenues of over 90% gross margins, directly to the bottom line.

Lifespot Health is expected to list on the ASX at \$0.20 share price in December 2016. The Company is raising AUD \$5M – 8M with an enterprise value (EV) of AUD \$6.85M ... at 5x, this is under \$60M fully diluted. On listing, it will be trading at an Enterprise Value/Revenue multiple of only 3.4X, cheaper than all its peers.

| ASX Code | Name | Listing/Relisting Date | Share Price on Listing | Market Cap on Listing | EV on Listing | EV/Rev on Listing | Current Share Price |
|------------|-----------------------------|------------------------|------------------------|-----------------------|----------------|-------------------|---------------------|
| EPT | ePAT Technologies | 19/10/2016 | \$0.02 | \$14.53M | \$10.38M | N/A | \$0.044 |
| OVN | Oventus Medical | 19/07/2016 | \$0.50 | \$36.00M | \$23.23M | 135.41x | \$0.745 |
| VHT | Volpara Health Tech | 27/04/2016 | \$0.50 | \$61.00M | \$51.00M | 21,170.61x | \$0.720 |
| JHL | Jayex Healthcare | 17/12/2015 | \$0.32 | \$48.31M | 50.30M | 11.53x | \$0.050 |
| MDR | MedAdvisor | 1/12/2015 | \$0.03 | \$20.61M | \$15.57M | 9.46x | \$0.041 |
| LSH | Lifespot Health | 5/12/2016 | \$0.20 | \$14.3M | \$6.07M | 3.4x | N/A |
| RAP | ResApp Health | 14/07/2016 | \$0.02 | \$11.24M | \$7.08M | N/A | \$0.480 |
| LBT | LBT Innovations | 31/07/2006 | \$0.20 | \$8.33M | \$4.96M | 1028.18x | \$0.64 |
| ACG | Atcor Medical Holdings | 9/11/2005 | \$0.50 | \$42.65M | \$28.00M | 22.62x | \$0.09 |
| MEB | Bioprospect Ltd/Medibio Ltd | 29/01/2001 | \$0.20 | \$8.26M | \$3.51M | N/A | \$0.46 |
| ADR | Adherium Limited | 26/08/2015 | \$0.50 | \$70.00M | \$37.14M | 12.78x | \$0.340 |

Please note: Lifespot Health is likely to be oversubscribed and you may not receive the full allocation bid for. Final bids are due 10am, Wednesday 7 December.

Please ensure you carefully read the prospectus before submitting your bid.

[CLICK HERE](#) to bid for stock

Contact

Richard Rouse
Head of Business Development
Peak Asset Management
M: +61-417-485-663
F: +61-3-9921-7100
Skype: richorouse
E: richard.rouse@peakassetmanagement.com.au
W: peakassetmanagement.com.au